Guided Therapeutics Inc (GTHP)

Name: Guided Therapeutics Inc (GTHP) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name GUIDED THERAPEUTICS INC · CIK 0000924515 · OTC · Electromedical & Electrotherapeutic Apparatus

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Guided Therapeutics Inc reported revenue of $767.0K. Over the twelve months to 2026-06-30, revenue was $650.0K.

Key ratios (year ended 2025-12-31)

74.4%

Gross margin

-309.3%

Operating margin

-416.7%

Net margin

n/m

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 10-Q (quarterly report) · 2026-08-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$650.0K	$767.0K	$7.0K	$98.0K	$13.0K	$81.0K	$102.0K	$36.0K	$57.0K	$244.0K	$0
Cost of Revenue	$158.0K	$196.0K	$5.0K	$62.0K	$81.0K	$61.0K	n/a	n/a	n/a	n/a	n/a
Gross Profit	$492.0K	$571.0K	$2.0K	$36.0K	-$68.0K	$20.0K	$143.0K	-$34.0K	-$32.0K	-$286.0K	$112.0K
R&D Expense	$340.0K	$469.0K	$526.0K	$228.0K	$77.0K	$69.0K	$143.0K	$122.0K	$244.0K	$334.0K	$733.0K
Operating Income	-$1.98M	-$2.37M	-$2.11M	-$3.46M	-$3.33M	-$2.36M	-$1.05M	-$937.0K	-$1.55M	-$3.12M	-$3.82M
Depreciation & Amortization	n/a	n/a	n/a	n/a	n/a	n/a	$0	$21.0K	$27.0K	$213.0K	$1.22M
EBITDA	n/a	n/a	n/a	n/a	n/a	n/a	-$1.05M	-$916.0K	-$1.52M	-$2.91M	-$2.60M
Net Income	-$3.06M	-$3.20M	-$2.42M	-$3.49M	-$4.34M	-$2.07M	-$279.0K	-$1.92M	$1.02M	-$10.70M	-$3.97M
EPS (Diluted)	n/a	-$0.04	-$0.05	-$0.07	-$0.15	-$0.18	-$0.04	-$0.58	$0.0138	$0.00	n/a
Total Assets	$1.20M	$1.32M	$1.38M	$1.67M	$3.37M	$2.04M	$1.35M	$1.18M	$236.0K	$406.0K	$1.49M
Total Liabilities	$6.96M	$7.33M	$6.27M	$5.47M	$6.25M	$7.49M	$12.21M	$18.11M	$16.06M	$19.81M	$10.76M
Long-Term Debt	$53.0K	n/a	n/a	n/a	n/a	$820.0K	$23.0K	$5.71M	$5.07M	$7.96M	n/a
Shareholders' Equity	-$5.76M	-$6.01M	-$4.89M	-$3.81M	-$2.88M	-$5.45M	-$10.86M	-$16.93M	-$15.82M	-$19.40M	-$9.27M
Cash & Equivalents	n/a	n/a	n/a	n/a	$2.31M	$643.0K	$182.0K	$899.0K	$0	$1.0K	$14.0K
Operating Cash Flow	-$1.50M	-$1.07M	-$1.12M	-$1.75M	-$1.48M	-$1.59M	-$1.88M	-$806.0K	-$1.36M	-$1.14M	-$1.80M
Capital Expenditures	n/a	$2.0K	$0	$0	$31.0K	$14.0K	$1.0K	$0	n/a	n/a	n/a
Free Cash Flow	n/a	-$1.07M	-$1.12M	-$1.75M	-$1.51M	-$1.61M	-$1.88M	-$806.0K	n/a	n/a	n/a
Shares Outstanding	96.54M	86.15M	65.13M	54.10M	48.60M	13.67M	13.1K	n/a	2.7K	62.0K	669
Weighted Average Diluted Shares	n/a	78.41M	57.34M	51.13M	32.51M	13.38M	10.8K	n/a	65.2K	n/a	n/a
EPS (Basic)	n/a	-$0.04	-$0.05	-$0.07	-$0.15	-$0.18	-$0.04	-$0.58	$1.95	$997.64	n/a